Goodwin Wins Deal Adviser of the Year at the 2026 European Lifestars Awards
Goodwin was named Deal Adviser of the Year at the 2026 European Lifestars Awards, held in London on November 16. The award recognized Goodwin for its exceptional expertise and impact in advising on life sciences transactions over the past year.
Goodwin’s UK Life Sciences practice represents companies in the biotechnology, pharmaceutical, and healthcare industries throughout the corporate lifecycle, as well as leading venture capital and investment firms. With offices in London and Cambridge, the integrated team draws on a longstanding commitment to the sector to help clients achieve their goals and improve patients’ lives.
Goodwin has particular expertise in advising emerging life sciences companies and their investors on early-stage financings, capital markets transactions, M&A, strategic collaborations, and licensing. The practice also advises on dispute resolution, regulatory, intellectual property, and data privacy matters.
In addition to this honor, Goodwin’s UK Life Sciences team is ranked Band 1 in Chambers UK for Life Sciences: Transactional and Tier 1 for Biotechnology (East Anglia) in The Legal 500 UK, where client feedback described Goodwin as an “absolutely stellar biotech team.”
Goodwin’s global Life Sciences industry group supports more than 2,500 private and public companies in the biotechnology, pharmaceutical, medtech, and healthcare industries, offering comprehensive services across every specialized life sciences discipline. The firm was recently named Healthcare and Pharmaceutical Corporate Practice of the Year at The American Lawyer Industry Awards.
The European Lifestars Awards recognize the exceptional individuals, teams, and organizations that have shaped the life sciences industry over the past 12 months.